Tag: size

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Grand Opening on June 30th Marks 11th Location in Austin Metro

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global In Silico Clinical Trials Market size & share revenue was valued at approximately USD 1.84 Billion in 2025 and is expected to reach USD 2.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 15.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Certara Inc., Simulations Plus Inc., Dassault Systèmes SE (SIMULIA/BIOVIA), Ansys Inc., Medidata Solutions (Dassault Systèmes), Insilico Medicine Ltd., Unlearn.AI Inc., Applied BioMath LLC, Rosa & Co. LLC, Entelos Inc., Pharsight Corporation (Certara) and others.

FDA-registered manufacturer examines growing use of high-concentration niacinamide formulas and reports that ingredient balance may play a greater role in product performance than active percentage alone.